EURUSD Bid: --
USDJPY Bid: --
GBPUSD Bid: --
USDCHF Bid: --
AUDUSD Bid: --
USDCAD Bid: --
NZDUSD Bid: --
EURGBP Bid: --
GBPJPY Bid: --
WTI Bid: --
BRENT Bid: --
XAUUSD Bid: --
XAGUSD Bid: --
SPX500 Bid: --
DAX40 Bid: --
US30 Bid: --
JPN225 Bid: --
NAS100 Bid: --
UK100 Bid: --
BTCUSD Bid: --
ETHUSD Bid: --
LTCUSD Bid: --
XRPUSD Bid: --
EURUSD Bid: --
USDJPY Bid: --
GBPUSD Bid: --
USDCHF Bid: --
AUDUSD Bid: --
USDCAD Bid: --
NZDUSD Bid: --
EURGBP Bid: --
GBPJPY Bid: --
WTI Bid: --
BRENT Bid: --
XAUUSD Bid: --
XAGUSD Bid: --
SPX500 Bid: --
DAX40 Bid: --
US30 Bid: --
JPN225 Bid: --
NAS100 Bid: --
UK100 Bid: --
BTCUSD Bid: --
ETHUSD Bid: --
LTCUSD Bid: --
XRPUSD Bid: --

Trump to announce new drug pricing agreement.

Posted: 31st Aug 2026

President Trump is set to announce another round of voluntary drug-pricing agreements today involving Bayer, Takeda, CSL and several midsized biotechnology companies.

Under the agreements, participating drugmakers are expected to provide “most-favored-nation,” or MFN, pricing on outpatient drugs purchased through state Medicaid programs. Prices would be tied more closely to the lower amounts paid in other developed countries, including Canada, Germany, France, Japan and the United Kingdom.

Some companies could also make selected medicines available directly to cash-paying patients through TrumpRx, bypassing insurance companies and pharmacy-benefit managers. In exchange, participating manufacturers could receive protection from pharmaceutical tariffs and potentially other regulatory benefits.

The Trump administration has already reached similar agreements with 17 major drugmakers, including Pfizer, Eli Lilly, Merck, Amgen, Johnson & Johnson, Novo Nordisk and AstraZeneca. It estimates the broader initiative could save federal and state Medicaid programs approximately $64.3 billion over 10 years.

The immediate benefits, however, appear to be concentrated on Medicaid programs and people buying selected medicines directly with cash. The announcement does not necessarily mean that Medicare beneficiaries or privately insured consumers will immediately pay less.

For the drug companies, the near-term earnings impact should be manageable because Medicaid represents only part of the U.S. market and companies already give rebates for their drugs to Medicaid recipients.  However, tariff relief helps offset some of the reduced pricing (Yes...tariffs raise prices). The larger earnings risk would come if MFN pricing were eventually expanded across Medicare and private insurance.

This article was written by Greg Michalowski at investinglive.com.

Source: Investing Live - News

Follow us on
Website Managed by BuiltByGo
Disclaimer: The information provided on FX Axe is for educational and informational purposes only and should not be construed as financial advice. Trading Foreign Exchange (FX), Contracts for Difference (CFDs), and other leveraged financial products involves a high level of risk and may not be suitable for all investors. Leverage can work both to your advantage and disadvantage, and as a result, you may lose more than your initial investment. Before deciding to trade FX, CFDs, or any other financial instrument, you should carefully consider your investment objectives, level of experience, and risk tolerance. You should not invest money that you cannot afford to lose. It is strongly advised that you seek independent financial advice if you have any doubts. FX Axe does not provide investment, tax, legal, or financial advice of any kind. We may receive compensation from brokers and partners featured on this website, but such relationships do not influence our reviews or recommendations. All reviews are based on our own opinions and research and should not be interpreted as endorsements or guarantees of any service. Past performance is not indicative of future results. The trading of FX and CFDs carries a significant risk of loss. By using this website, you acknowledge that FX Axe bears no responsibility for any losses you may incur from your trading activities or reliance on information provided here.

Affiliate Disclosure: Some of the links and references on FX Axe may relate to third-party brokers or service providers. In certain cases, we may receive compensation if you choose to engage with these providers through our website. This helps support the ongoing operation of the site and allows us to continue publishing content at no direct cost to our readers. Our content is created with the aim of being informative and useful. While commercial relationships may exist, we strive to ensure that the information presented remains objective and based on our own research and perspective.
cross